Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology

Benjamin Kelmendi; Thomas G. Adams; Steven Southwick; Chadi G. Abdallah; John H. Krystal

doi:10.1111/cpsp.12202

Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology

Benjamin Kelmendi, Thomas G. Adams, Steven Southwick, Chadi G. Abdallah, John H. Krystal

Psychology

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Thirty years of research on the biology of posttraumatic stress disorder now provides a foundation for hypotheses related to the mechanisms underlying the pharmacotherapy of this disorder. Only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration for the treatment of PTSD. Although these medications are somewhat effective, other treatment mechanisms must be explored to address the unmet need for effective treatment. This article provides a concise summary of advances in our understanding of the neurobiology of PTSD and novel approaches to pharmacotherapy.

Original language	English
Pages (from-to)	281-297
Number of pages	17
Journal	Clinical Psychology: Science and Practice
Volume	24
Issue number	3
DOIs	https://doi.org/10.1111/cpsp.12202
State	Published - Sep 2017

Bibliographical note

Publisher Copyright:
Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Keywords

gamma-amino-butyric acid
glutamate
noradrenergic
pharmacology
posttraumatic stress disorder
serotonin

ASJC Scopus subject areas

Clinical Psychology

Access to Document

10.1111/cpsp.12202

Cite this

@article{c69e9cad264a4fcbafbd97b7b714a7e5,

title = "Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology",

abstract = "Thirty years of research on the biology of posttraumatic stress disorder now provides a foundation for hypotheses related to the mechanisms underlying the pharmacotherapy of this disorder. Only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration for the treatment of PTSD. Although these medications are somewhat effective, other treatment mechanisms must be explored to address the unmet need for effective treatment. This article provides a concise summary of advances in our understanding of the neurobiology of PTSD and novel approaches to pharmacotherapy.",

keywords = "gamma-amino-butyric acid, glutamate, noradrenergic, pharmacology, posttraumatic stress disorder, serotonin",

author = "Benjamin Kelmendi and Adams, {Thomas G.} and Steven Southwick and Abdallah, {Chadi G.} and Krystal, {John H.}",

note = "Publisher Copyright: Published 2017. This article is a U.S. Government work and is in the public domain in the USA.",

year = "2017",

month = sep,

doi = "10.1111/cpsp.12202",

language = "English",

volume = "24",

pages = "281--297",

number = "3",

}

TY - JOUR

T1 - Posttraumatic Stress Disorder

T2 - An Integrated Overview of the Neurobiological Rationale for Pharmacology

AU - Kelmendi, Benjamin

AU - Adams, Thomas G.

AU - Southwick, Steven

AU - Abdallah, Chadi G.

AU - Krystal, John H.

N1 - Publisher Copyright: Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

PY - 2017/9

Y1 - 2017/9

N2 - Thirty years of research on the biology of posttraumatic stress disorder now provides a foundation for hypotheses related to the mechanisms underlying the pharmacotherapy of this disorder. Only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration for the treatment of PTSD. Although these medications are somewhat effective, other treatment mechanisms must be explored to address the unmet need for effective treatment. This article provides a concise summary of advances in our understanding of the neurobiology of PTSD and novel approaches to pharmacotherapy.

AB - Thirty years of research on the biology of posttraumatic stress disorder now provides a foundation for hypotheses related to the mechanisms underlying the pharmacotherapy of this disorder. Only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration for the treatment of PTSD. Although these medications are somewhat effective, other treatment mechanisms must be explored to address the unmet need for effective treatment. This article provides a concise summary of advances in our understanding of the neurobiology of PTSD and novel approaches to pharmacotherapy.

KW - gamma-amino-butyric acid

KW - glutamate

KW - noradrenergic

KW - pharmacology

KW - posttraumatic stress disorder

KW - serotonin

UR - http://www.scopus.com/inward/record.url?scp=85024873090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024873090&partnerID=8YFLogxK

U2 - 10.1111/cpsp.12202

DO - 10.1111/cpsp.12202

M3 - Review article

AN - SCOPUS:85024873090

SN - 0969-5893

VL - 24

SP - 281

EP - 297

JO - Clinical Psychology: Science and Practice

JF - Clinical Psychology: Science and Practice

IS - 3

ER -

Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this